Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. (Q53028366)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 August 2014

Language	Label	Description	Also known as
English	Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.	scientific article published on 11 August 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

author name string

Elena N Klyushnenkova

1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Vladimir B Riabov

2

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Diana V Kouiavskaia

3

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Ashley Wietsma

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Min Zhan

5

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Richard B Alexander

6

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

publication date

11 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

74

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

14

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

1423-1432

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Basic principles of tumor-associated regulatory T cell biology

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Regulatory T cells: mechanisms of differentiation and function

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Identifiers

10.1002/PROS.22858

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53028366&oldid=1248299781"